Carterra
Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput LSA™ instrument for monoclonal antibody (mAb) discovery and characterization combines patented microfluidics technology with real-time array Surface Plasmon Resonance (SPR) and industry leading data analysis and visualization software, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. The LSA provides customers with mAb characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage.
Carterra LSA-XT
Disruptive Technology for Screening and Characterization. Enhanced sensitivity and fast data collection rate build upon unmatched capabilities in throughput and enable assays such as TPDs/PROTAC®s, ki...
Carterra Ultra™
Disruptive technology for the characterization of small molecules and fragments. With enhanced sensitivity, expanded thermal options, and advanced microfluidics, the Carterra Ultra™ platform is our mo...
Browse Products by Field
Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput LSA™ instrument for monoclonal antibody (mAb) discovery and characterization combines patented microfluidics technology with real-time array Surface Plasmon Resonance (SPR) and industry leading data analysis and visualization software, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. The LSA provides customers with mAb characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage.